Radiation therapy for life- or function-threatening infant hemangioma

Area of Science:

• Pediatric Oncology
• Radiation Oncology
• Vascular Malformations

Background:

• Hemangiomas are common benign tumors in infants.
• Life- or function-threatening hemangiomas require prompt and effective treatment.
• Radiation therapy is a potential treatment modality for complex infant hemangiomas.

Purpose of the Study:

• To evaluate the efficacy and long-term results of radiation therapy for infants with life- or function-threatening hemangiomas.
• To assess treatment outcomes in patients with Kasabach-Merritt syndrome.
• To determine the safety and potential morbidities associated with radiation therapy in this population.

Main Methods:

• A cohort of 13 infants (0-8 months) with hemangiomas received radiation therapy.
• Treatment protocols varied based on hemangioma severity (life- vs. function-threatening).
• Median radiation dose was 10 Gy, with evaluation for residual disease, skin changes, and functional deficits.

Main Results:

• All patients with Kasabach-Merritt syndrome experienced hemangioma regression and normalized platelet counts within 40 days.
• Most patients (excluding KMS) achieved symptom relief within 40 days.
• One patient required reirradiation due to relapse; one experienced severe long-term radiation-related morbidity.

Conclusions:

• Radiation therapy, with doses up to 10 Gy, is a viable treatment for life-threatening hemangiomas.
• It is also indicated for select cases of function-threatening hemangiomas.
• Careful patient selection and monitoring are essential to optimize outcomes and minimize risks.